PhytoPharm
Updating the operating model
- Biotechnology
- January 2026
A4BEE prepared this analysis from publicly available sources. It reflects our own reading of PhytoPharm's published strategy and is not endorsed by, or produced in cooperation with, PhytoPharm. Company website
Strategic priorities
PhytoPharm operates across 4 stated priorities, with the most concrete near-term plan anchored on go zero 2030 climate neutrality.
Commitment to achieving carbon neutrality across Scopes 1, 2, and 3 emissions by 2030, requiring real-time data collection from agricultural supply chains spanning 80+ countries.
Operational efficiency target to reduce product and material waste by end of 2025 through real-time yield monitoring and AI-driven process optimization.
Scaling plant-based molecular pharming technology from laboratory to 5 million vaccine doses per month production capacity, enabling faster, cheaper biologics development.
-
01
Go Zero 2030 Climate Neutrality
Commitment to achieving carbon neutrality across Scopes 1, 2, and 3 emissions by 2030, requiring real-time data collection from agricultural supply chains spanning 80+ countries.
-
02
17.5% Material Loss Reduction
Operational efficiency target to reduce product and material waste by end of 2025 through real-time yield monitoring and AI-driven process optimization.
-
03
BaiyaPharming Platform Acceleration
Scaling plant-based molecular pharming technology from laboratory to 5 million vaccine doses per month production capacity, enabling faster, cheaper biologics development.
-
04
100% Digital Lab for ATMPs
Achieving complete laboratory digitalization to meet EMA 2024 ATMP compliance requirements with automated documentation and full data integrity for regulatory audits.
Challenges we see
- Operations Manufacturing
Legacy Infrastructure at 75-Year-Old Klęka Facility
The Klęka pharmaceutical plant has been operational since 1949 and relies on fragmented legacy Industrial PCs (IPCs) and SCADA systems that cannot support modern real-time data acquisition.
Single points of failure in the legacy stack could halt all data collection for a batch, risking GMP compliance and causing costly production delays.
- Operations Manufacturing
Extraction Yield Instability from Raw Material Variability
Phytopharmaceutical production handles over 200 raw materials subject to environmental fluctuations affecting active ingredient concentration, currently managed through subjective monitoring and retrospective analysis.
Without real-time data acquisition from extraction vats, the 17.5% loss reduction target by 2025 is likely unachievable, directly impacting profitability and sustainability goals.
- ESG Regulatory
Scope 3 Emissions Data Gap Across Global Supply Chain
Approximately 50% of The Nature Network's emissions originate from agricultural fields across 80+ countries, requiring transition from generic estimates to real-time verified data for climate neutrality commitment.
Inability to collect and contextualize diverse data streams (weather, soil health, transportation) into a corporate carbon footprint jeopardizes the Go Zero 2030 commitment and regulatory compliance.
- Digital Operations
Digital Hesitancy and Black Box Anxiety in BaiyaPharming Operations
As Baiya implements AI-driven control for protein expression systems, researchers maintain systems in "Manual Mode" due to distrust of automation algorithms and lack of understanding of underlying processes.
This "Trust Deficit" caps full utilization of automation investments, slowing the bench-to-bedside timeline and threatening competitive advantage in plant-based biologics.
- Digital Integration
Fragmented IT/OT Environments and Manual Data Entry Persistence
Despite having 70 proprietary APIs and over 100 products, critical data flows are interrupted by manual Excel entry and paper notebooks, creating "Excel Islands" where bioprocess data is disconnected from live trends.
This fragmentation threatens data integrity for FDA/GMP audits and prevents scientists from accessing real-time insights needed for process optimization.
Opportunities, by urgency and business impact
Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.
-
Real-Time Yield Monitoring for Extraction Processes
Current yield management relies on subjective operator monitoring and retrospective analysis, making it impossible to optimize extraction in real-time or predict losses before they occur.
Implement IoT-enabled data acquisition systems with AI-driven yield optimization algorithms to achieve the 17.5% material loss reduction target through predictive process control.
-
Unified Industrial Data Platform for Carbon Tracking
Scope 3 emissions data from 80+ agricultural sourcing countries exists in fragmented, non-standardized formats, making it impossible to generate accurate real-time carbon footprint reports.
Deploy an ontology-based Industrial Data Platform capable of ingesting diverse data streams and contextualizing them into automated sustainability reports for regulatory compliance.
-
High-Availability Infrastructure for Zero-Downtime Operations
Legacy standalone Industrial PCs create single points of failure where hardware malfunction can halt all data collection, risking batch integrity and GMP compliance.
Migrate to clustered High-Availability architecture with containerized workloads that can smooth migrate between nodes, ensuring continuous operation.
-
Digital Trust Building for Automated Bioprocessing
Highly skilled scientists at Baiya exhibit "Black Box Anxiety" toward automation, keeping systems in Manual Mode and preventing ROI realization on digital investments.
Deploy UX-driven interface redesigns and "Sandbox" environments that allow operators to test automation safely, building trust through transparency and structured onboarding.
-
Paperless Laboratory Operations for ATMP Compliance
Manual data entry and paper notebooks create data integrity risks that threaten compliance with EMA's 2024 ATMP regulatory updates requiring detailed risk-based manufacturing quality control.
Implement Laboratory Execution Systems with automated data capture from instruments directly to LIMS, achieving 100% data integrity and eliminating manual transcription errors.
What we'd propose
- Digital CDMO
Digital Manufacturing & Machine Retrofitting
Retrofit legacy extraction and manufacturing equipment at the Klęka facility with IoT sensors and data acquisition systems to enable real-time yield monitoring and predictive process control without disrupting existing GMP certifications.
-
OT/IT convergence
DETAIL
-
Batch intelligence
DETAIL
-
Production release flow
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
- Enterprise AI
Industrial Data Platform for Sustainability Intelligence
Build an ontology-based data platform that automatically ingests, contextualizes, and reports on carbon emissions data from agricultural supply chains across 80+ countries to support Go Zero 2030 compliance.
-
Ontology layer
DETAIL
-
Predictive models
DETAIL
-
Decision surfaces
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
- Digital Lab
High-Availability Cluster Architecture Migration
Transition from fragile legacy Industrial PCs to a resilient containerized cluster environment that ensures zero-downtime operations and enables smooth hardware failure recovery across all manufacturing and R&D sites.
-
Unified data backbone
DETAIL
-
Paperless workflows
DETAIL
-
Continuous QC release
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
- Digital Lab
Digital Onboarding & Change Management for BaiyaPharming
Deploy a comprehensive culture change program that transforms Baiya scientists from "Digital Hesitant" manual operators into confident "Digital Operators" who trust and effectively utilize automation systems.
-
Unified data backbone
DETAIL
-
Paperless workflows
DETAIL
-
Continuous QC release
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
- Digital Lab
Digital Lab & Laboratory Execution System for ATMP Compliance
Implement a fully integrated Laboratory Execution System (LES) that automates data capture from all analytical instruments, eliminates paper-based workflows, and ensures 100% data integrity for EMA ATMP regulatory submissions.
-
Unified data backbone
DETAIL
-
Paperless workflows
DETAIL
-
Continuous QC release
DETAIL
- Shorter lead time from data capture to decision.
- Records that audit on their own, not on inspection day.
- Scale without adding the same headcount.
-
Digital maturity: today and target
Scored out of 100 across six dimensions. The target is what PhytoPharm's own published ambition implies — not a perfect score.
- Data Connectivity 35 → 85
- Legacy SCADA systems and manual data entry create fragmented "Excel Islands"; target requires unified OPC UA connectivity across all sites
- Process Automation 40 → 80
- "Subjective monitoring" persists in extraction processes; target requires AI-driven closed-loop control for yield optimization
- Supply Chain Transparency 25 → 90
- Scope 3 data relies on "generic estimates" from 80+ countries; target requires real-time IoT-enabled carbon tracking
- Regulatory Compliance Infrastructure 50 → 95
- Paper-based workflows risk ATMP compliance; target requires automated audit trails meeting EMA 2024 ATMP standards
- Workforce Digital Adoption 30 → 75
- "Digital Hesitancy" and "Black Box Anxiety" limit automation utilization; target requires comprehensive change management
- Infrastructure Resilience 35 → 90
- Single points of failure in legacy IPCs; target requires N+1 redundant High-Availability cluster architecture
Check this yourself
Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.
-
Self-assessment
Electronic Batch Record (eBR) Readiness
Check how far your batch records are from paperless, and what the next step is.
-
Self-assessment
Data & AI Maturity
See how ready your data actually is for the AI work you're planning.
-
Market comparison
European CDMOs Compared
The 2026 landscape: who does what, at what scale.
-
Market comparison
Pharma Data Platform Use Cases — Ranked
Use cases ranked by how hard they are against what they're worth.
Think we've read this right?
Talk to usRelated reading
-
Still biotech or already techbio?
The results of a Tech Imperatives for biotech 2022 report indicate changes in biotech production and management.
-
From Paper to Performance: Operational Efficiency and Compliance in Labs
Transform your QC lab with scalable digital solutions that embed compliance, boost efficiency, and deliver a future-ready competitive edge.
-
Addressing sustainability in pharma & biotech
At A4BEE, we combine company social responsibility and sustainability needs with the path set by the company’s values and mission.
-
Lab of Tomorrow: We’re at a Turning Point – Is Your Lab on the Right Track?
Do you know what the biggest paradox is? Biotech and pharma fully understand that digitization is the future. Most of them know that effective market competition is simply not possible without artificial intelligence, automation, and data analysis. And yet, many labs are still stuck in the past, working in isolation, manually analyzing data, and losing the potential that technology offers.
-
Digital Twin Maturity Model – self-assessment tool
Initially, defining what a digital twin even is seemed simple - we have a real product and its virtual counterpart, and we combine the two.
This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with PhytoPharm, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].